This initiative is part of the brand’s commitment to providing guests with science-backed health and wellness services.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Alternatively, foods containing ingredients that naturally contain B3, such as poultry, red meat, fish, eggs, peanuts, brown ...

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

The buzzy supplement is beloved by celebrities and starting to show up in skin care. But what can it actually do?

Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement ...

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides ...

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook May 07, 2025 4:02 PM ET Niagen Bioscience, Inc. (NAGE) ...

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics ...

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net ...